Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

NCT00539864 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

602

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: FluBlok Influenza Vaccination
BIOLOGICAL: TIV (Fluzone) Influenza Vaccination

Sponsor

Protein Sciences Corporation